top of page
ResolutionRx Ltd, an unlisted public Australian company, is focused on developing and commercializing proprietary pharmaceutical cannabinoids. RespireRx Pharmaceuticals Inc.
ResolutionRx is engaging in the research and development (R&D) associated with that program, initially for the development of a new formulation of dronabinol to be tested in a Phase 3 clinical trial and in the filing of regulatory approval for the treatment of obstructive sleep apnoea ("OSA")
The term cannabinoid refers to pharmacologically active substances originally found in the cannabis plant that led to the discovery of the body’s own cannabinoids, termed endocannabinoids.
Obstructive Sleep Apnoea
Obstructive Sleep Apnoea (OSA) is associated with decreased quality of life, and significant functional impairment. According to an August 2019 publication in Lancet Respiratory Medicine, afflicts more than 90 million people in the United States, Australia, Germany and the United Kingdom.
ResolutionRx has obtained the rights from RespireRx, to develop and commercialize cannabinoids such as dronabinol for sleep related and other breathing disorders.
bottom of page